GeneDx Fuels Rare Disease Drug Discovery with Launch of GeneDx Discover
GeneDx Holdings Corp. - Class A (WGS)
Company Research
Source: Business Wire
New Biopharma Solution Aims to Accelerate the Delivery of Precision Medicine to More Patients STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced GeneDx Discover, a first-of-its-kind data visualization tool, which provides biopharmaceutical companies access to deidentified and aggregated genetic data - powered by GeneDx’s robust database - to improve all stages of drug development. The new offering is part of GeneDx’s ongoing investment to deliver personalized and actionable health insights to inform diagnosis, direct treatment, and improve drug discovery.Today’s drug discovery and development process is not scalable to meet society’s growing needs. On average, developing a new therapy costs $2.6B, takes 12 years, and fails 90% of the time. This data represents today's long and expensive clinical development cycles that too often fail due to safety and/or efficacy issues.1,2 These high cos
Show less
Read more
Impact Snapshot
Event Time:
WGS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
WGS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
WGS alerts
High impacting GeneDx Holdings Corp. - Class A news events
Weekly update
A roundup of the hottest topics
WGS
News
- GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate SecretaryBusiness Wire
- Meet the Healthcare Stock That Produced Nvidia-Sized Gains in Less Than a Year [Yahoo! Finance]Yahoo! Finance
- New GeneDx Study Reveals Racial Disparities in Genetic Diagnosis Due to Systemic Barriers, Not Diagnostic YieldsBusiness Wire
- GeneDx to Highlight Key Research Findings at American Society of Human Genetics (ASHG) Annual MeetingBusiness Wire
- GeneDx Holdings Corp. (NASDAQ: WGS) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $54.00 to $70.00. They now have a "neutral" rating on the stock.MarketBeat
WGS
Earnings
- 10/29/24 - Miss
WGS
Sec Filings
- 11/21/24 - Form 144
- 11/20/24 - Form SC
- 11/19/24 - Form SC
- WGS's page on the SEC website